{
    "clinical_study": {
        "@rank": "90710", 
        "arm_group": [
            {
                "arm_group_label": "MLN0128 + MLN1117 Arm A", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "MLN0128 + MLN1117 Arm B", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is a multicenter, open-label, phase 1b trial of MLN0128 (an oral mTORC1/2\n      inhibitor) in combination with MLN1117 (an oral inhibitor of the PI3K (alpha) isoform) when\n      administered to adult patients with advanced nonhematological malignancies."
        }, 
        "brief_title": "Phase 1b Study of MLN0128 in Combination With MLN1117 in Adult Patients With Advanced Nonhematologic Malignancies", 
        "completion_date": {
            "#text": "November 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Advanced Nonhematologic Malignancies", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female patients 18 years or older\n\n          -  Patients must have a diagnosis and documented disease progression of a solid tumor\n             malignancy, excluding primary brain tumor, for which standard, curative, or life\n             prolonging treatment does not exist or is no longer effective\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Female subjects who are postmenopausal for at least 1 year prior to screening. For\n             women of child-bearing potential agree to practice 2 effective methods of\n             contraception, or agree to practice true abstinence\n\n          -  Male subjects must agree to practice effective barrier contraception during the\n             entire study treatment period and through 30 days after last dose of study drug or\n             practice true abstinence\n\n          -  Voluntary written consent\n\n          -  Suitable venous access\n\n          -  Patients must have a block of banked tumor tissue and/or fresh tumor tissue or at\n             least 10 unstained slides available to be sent to the central laboratory\n\n          -  Clinical laboratory values as specified in the protocol\n\n          -  Patients must have radiographically or clinically evaluable tumor\n\n        Exclusion Criteria:\n\n          -  Female patients who are lactating and breastfeeding or have a positive serum\n             pregnancy test during the Screening period or a positive urine pregnancy test on Day\n             1 before first dose of study drug\n\n          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,\n             potentially interfere with the completion of treatment\n\n          -  Treatment with any investigational products within 30 days before the first dose of\n             study drug\n\n          -  Previous treatment with MLN1117 and/or MLN0128; previous treatment with dual mTORC1/2\n             or dual PI3K-mTOR inhibitors\n\n          -  Failed to have recovered from the reversible effects of previous anticancer therapies\n\n          -  Have received systemic corticosteroid (inhalers are allowed) within 7 days before the\n             first administration of study drug\n\n          -  Known gastrointestinal (GI) disease or GI procedure that could interfere with the\n             oral absorption or tolerance of study drug\n\n          -  Diagnosis of diabetes mellitus\n\n          -  Other clinically significant co-morbidities, such as uncontrolled pulmonary disease,\n             active CNS disease, active infection\n\n          -  Known human immunodeficiency virus (HIV) infection\n\n          -  Cardiovascular conditions as defined in the protocol\n\n          -  A requirement for positive inotropic support (excluding digoxin) or serious\n             uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation) within 1 year\n             before screening\n\n          -  Patients who are taking strong or moderate CYP3A4 inhibitors, strong CYP2C9 or\n             CYP2C19 inhibitors or clinically significant inducers of CYPs 3A4, 2C9, or 2C19\n             within 2 weeks of the first dose of MLN0128 + MLN1117, or patients who require\n             treatment with these agents during the trial. Patients who are taking proton pump\n             inhibitors within 7 days of the first dose or who require treatment with proton pump\n             inhibitors during the trial or those who are taking H2 receptor antagonists within 24\n             hours of the first dose\n\n          -  Patients who received previous therapy with PI3K inhibitors or rapalogs will be\n             allowed in the study if all other inclusion/exclusion criteria are met\n\n          -  Diagnosis of primary brain tumor or symptomatic brain metastasis. Patients with brain\n             metastases must be without neurologic dysfunction that would confound the evaluation\n             of neurologic and other AEs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "152", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01899053", 
            "org_study_id": "C32001", 
            "secondary_id": "2013-000466-11"
        }, 
        "intervention": [
            {
                "arm_group_label": "MLN0128 + MLN1117 Arm A", 
                "description": "MLN0128 and MLN1117 will be administered in combination to subjects for 3 days each week.", 
                "intervention_name": "MLN0128 + MLN1117 Arm A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MLN0128 + MLN1117 Arm B", 
                "description": "MLN0128 and MLN1117 will be administered in combination to subjects for 3 days each week.", 
                "intervention_name": "MLN0128 + MLN1117 Arm B", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Solid tumors", 
            "MLN0128", 
            "MLN1117"
        ], 
        "lastchanged_date": "February 12, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Howard Burris"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute (SCRI)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Drew Rasco"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "South Texas Accelerated Research Therapeutics (START)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Open-label, Phase 1b Study of MLN0128 (an Oral mTORC1/2 Inhibitor) in Combination With MLN1117 (an Oral PI3K\u03b1 Inhibitor) in Adult Patients With Advanced Nonhematologic Malignancies", 
        "overall_contact": {
            "email": "medical@mlnm.com", 
            "last_name": "For an updated listing of recruitment sites contact: Millennium Medical and Drug Information Center", 
            "phone": "1-877-674-3784"
        }, 
        "overall_official": {
            "affiliation": "Millennium Pharmaceuticals, Inc.", 
            "last_name": "Medical Monitor", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Europe: European Medicines Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Adverse events (AEs), serious adverse events (SAEs), assessments of clinical and laboratory values, and vital sign measurements", 
                "measure": "Number of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "From signing of the informed consent form through 30 days after the last dose of study drug"
            }, 
            {
                "description": "Including but not limited to:\nCmax,Tmax, area under the concentration-time curve (AUC) from time 0 to the end of the dosing interval (AUC0-last), t1/2, apparent oral clearance (CL/F), peak-to-trough ratio, and accumulation ratio.", 
                "measure": "MLN0128 and MLN1117 plasma PK parameters", 
                "safety_issue": "No", 
                "time_frame": "At screening, Day 1, Day 2, Day 24, and Day 25"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01899053"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Measures of disease response including objective response rate and duration of response, based on investigator's assessment and using if feasible, the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)", 
            "measure": "Measures of disease response", 
            "safety_issue": "No", 
            "time_frame": "At screening, Days 22 to 28 of Cycle 2 and every even numbered cycle thereafter"
        }, 
        "source": "Millennium Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Millennium Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}